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The ability to generate spinal cord motor neurons from human pluripotent stem
cells (hPSCs) is of great use for modelling motor neuron–based diseases and
cell-replacement therapies. A key step in the design of hPSC differentiation
strategies aiming to produce motor neurons involves induction of the appro-
priate anteroposterior (A-P) axial identity, an important factor influencing mo-
tor neuron subtype specification, functionality, and disease vulnerability. Most
current protocols for induction of motor neurons from hPSCs produce predom-
inantly cells of a mixed hindbrain/cervical axial identity marked by expression
of Hox paralogous group (PG) members 1-5, but are inefficient in generating
high numbers of more posterior thoracic/lumbosacral Hox PG(8-13)+ spinal
cordmotor neurons. Here, we describe a protocol for efficient generation of tho-
racic spinal cord cells and motor neurons from hPSCs. This step-wise protocol
relies on the initial generation of a neuromesodermal-potent axial progenitor
population, which is differentiated first to produce posterior ventral spinal cord
progenitors and subsequently to produce posterior motor neurons exhibiting a
predominantly thoracic axial identity. © 2021 The Authors. Current Protocols
published by Wiley Periodicals LLC.
Basic Protocol 1: Differentiation of neuromesodermal progenitors
Basic Protocol 2: Posterior ventral spinal cord progenitor differentiation
Basic Protocol 3: Posterior motor neuron differentiation
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INTRODUCTION
During embryonic development, motor neurons (MNs) arise from a set of progenitors
within the ventral spinal cord, from which they mature and project axons to innervate
target muscles. Multiple MN subtypes are specified across the anterior-posterior (A-P)
axis of the spinal cord, allowing for innervation of the diverse axial-level-dependent mus-
cle targets (reviewed in Sagner & Briscoe, 2019). The specification of MNs across the
A-P axis of the spinal cord is largely regulated by a family of homeobox genes known
as HOX genes (Dasen, Liu, & Jessell, 2003; Dasen, Tice, Brenner-Morton, & Jessell,
2005, 2008; Jung et al., 2010). Hox genes are arranged as paralogous groups (PG) 1-13
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across four distinct chromosomal clusters (A-D) and are expressed along the post-cranial
A-P axis in a strict spatiotemporal manner reflecting their 3′-to-5′ genomic order: hind-
brain/cervical MNs are marked by Hox PG(1-5), whereas more posterior thoracic and
lumbosacral MNs are marked by Hox PG(6-9) and Hox PG(10-13), respectively.
Damage or degeneration of MNs results in a large array of movement-based disorders.
In vitro production of MNs from human pluripotent stem cells (hPSCs) has provided
a useful tool for in vitro modelling of these neurodegenerative diseases as well as cell
therapy applications, e.g., for treatment of spinal cord injuries. Most conventional hPSC
differentiation protocols for generation ofMNs rely predominantly on initial induction of
an anterior neural identity that is successively patterned to a ventral spinal cord/MN fate
through exposure to sonic hedgehog (SHH) and retinoic acid signals (Amoroso et al.,
2013; Lee et al., 2007; Li et al., 2008; Peljto, Dasen, Mazzoni, Jessell, & Wichterle,
2010; Wichterle, Lieberam, Porter, & Jessell, 2002). However, MNs produced in these
protocols predominantly exhibit a Hox PG(1-5)+ hindbrain/cervical character, with low
yields of the more posterior Hox PG(8-13)+ thoracic/lumbosacral MNs.
We recently described an efficient protocol for generation of posterior motor neurons
that mainly display a thoracic axial identity (Wind et al., 2021). Our strategy is based on
initial induction of a neuromesodermal progenitor (NMP)–like population from hPSCs
following treatment with WNT and FGF signaling pathway agonists (Frith et al., 2018;
Gouti et al., 2014; Lippman et al., 2015). In vivo, NMPs are posteriorly located bipotent
progenitors that give rise to neural and mesodermal cells of the post-cranial axis during
embryonic development (Tzouanacou, Wegener, Wymeersch, Wilson, & Nicolas, 2009;
Wymeersch et al., 2016; reviewed inWymeersch, Wilson, & Tsakiridis, 2021). These are
subsequently steered toward a ventral spinal cord progenitor state via active suppression
of the pro-dorsal TGF-β and BMP signaling pathways in addition to SHH/retinoic acid
signaling stimulation, which eventually gives rise to posterior MNs following culture
in neurotrophic medium (Wind et al., 2021). Here we provide an in depth step-by-step
description of this approach.
BASIC
PROTOCOL 1
DIFFERENTIATION OF NEUROMESODERMAL PROGENITORS
The initial step of the differentiation protocol depends upon the high yield generation of
NMP-like cells from hPSCs driven by simultaneous stimulation of the WNT and FGF
signaling pathways and inhibition of BMP activity (Fig. 1A) to limit induction of neural
crest progenitors (Frith et al., 2018). These are marked by the co-expression of TBXT
and SOX2, transcriptional factors indicative of a mesodermal and neural identity, respec-
tively. Moreover, NMP cultures exhibit expression of other posteriorly expressed genes,
such as NKX1-2, CDX2 and Hox family members.
Materials
0.6 mg/ml vitronectin (Thermo Fisher Scientific, cat. no. A31804), stored in
200-µl aliquots at −80°C
Sterile PBS
Human pluripotent stem cells (hPSCs) grown to 60%-80% confluency
5 mM UltraPure EDTA, pH 8.0 (Thermo Fisher Scientific, cat. no. 15575020) in
sterile PBS, stored at 4°C
DMEM F-12 medium with 15 mM HEPES, without l-glutamine (Sigma, cat. no.
D6421)
N2B27 medium (see recipe), freshly prepared
Antibodies for confirming cell identity:
Anti-SOX2 (Abcam, cat. no. ab92494, RRID AB_10585428)




Figure 1 In vitro differentiation of NMP-like cells from hPSCs. (A) Culture conditions used for in-
duction of NMPs. (B) Representative brightfield images of NMP-like cells on day 3. (C) Immunoflu-
orescence images showing co-expression of SOX2 and TBXT, which defines the NMP state.
Multiwell cell culture plates
37°C/5% CO2 incubator
15-ml conical tubes (Falcon)
Hemocytometer
Additional reagents and solutions for standard antibody staining protocols
Day 0: Prepare vitronectin-coated plates 30 min before use
1. Thaw an aliquot of 0.6 mg/ml vitronectin stock at room temperature.
As a general guide, 150 μl of prepared solution per cm2 should allow full coverage, which
will require 1.5 μl of stock solution per cm2.
The total number of wells needed will depend on the user’s needs and extent of analysis.
We typically employ 12-well plates and include an extra 20 wells for confirming cell
identities throughout the process, as follows: 2 wells for qPCR on days 3, 8, 14, and 24;
2 wells for immunofluorescence on days 3 and 14; 4 wells for immunofluorescence on
days 8 and 24.
2. Dilute 1:100 with sterile PBS (final 6 μg/ml).
3. Cover the entire surface of multiwell plates with vitronectin (150 μl/cm2) and incu-
bate 1 hr at room temperature or overnight at 37°C/5% CO2.





Day 0: Seed hPSCs
4. Aspirate medium from hPSCs with a confluency of 60%-80%.
5. Add enough 5 mM EDTA to cover the cells (150 μl/cm2) and incubate 5 min at
37°C/5% CO2.
6. Aspirate EDTA and apply DMEM-F12 medium (150 μl/cm2) to lift cells as small
clumps.
7. Transfer suspended cells to a 15-ml Falcon tube and spin 4 min at 200 × g.
8. Resuspend cell pellet in 1 ml freshly prepared N2B27 medium supplemented with
10 µM Y-27632.
Small molecules and recombinant proteins should be added to medium fresh each day.
9. Count cells in a 10-µl aliquot using a hemocytometer.
10. Aspirate vitronectin from the culture plates and add 150 μl/cm2 N2B27mediumwith
10 µM Y-27632 to each well.
11. Plate cells at a density of 60,000 cells/cm2.
12. Rock gently to distribute the cells evenly across the wells and incubate overnight at
37°C/5% CO2.
Day 1: Replenish medium
13. Aspirate medium and replace with freshly prepared N2B27 medium without Y-
27632.
Y-27632 should be included only for the first 24 hr of differentiation.
14. Incubate until day 3 at 37°C/5% CO2.
NMP differentiation is complete on day 3. Cells should appear as a confluent monolayer
(see Fig. 1B).
Day 3: Assess differentiation
15. On day 3, confirm the NMP cell type by antibody staining.
Successfully differentiated NMPs should co-express TBXT and SOX2 (Fig. 1C). Efficient
induction of CDX2 and other genes denoting a posterior axial identity (as reviewed by
Wymeersch et al., 2021) can also be assessed by immunostaining/qPCR.
BASIC
PROTOCOL 2
DIFFERENTIATION OF POSTERIOR VENTRAL SPINAL CORD
PROGENITORS
This protocol encompasses the directed differentiation of human NMPs to a posterior
ventral spinal cord identity. It relies on combined BMP and TGF-β inhibition and sup-
plementation by retinoic acid and SHH agonist signals (Figs. 2A, 3A) to first promote
generation of HOXC9+/SOX1+/PAX6+ posterior neurectoderm cells and subsequently
induce differentiation of ventral spinal cord progenitors.
Materials
NMPs (see Basic Protocol 1)
Geltrex LDEV-Free Reduced Growth Factor Basement Membrane Matrix (Thermo
Fisher Scientific, cat. no. A1413201), stored in 100-µl aliquots at −80°C
DMEM F-12 medium with 15 mM HEPES, without l-glutamine (Sigma, cat. no.
D6421)
Accutase (Sigma, cat. no. A6964)





Figure 2 In vitro differentiation of posterior neurectoderm. (A) Culture conditions used for in-
duction of posterior neurectoderm. (B) Representative images of cells after successful poste-
rior neurectoderm differentiation. (C) Immunofluorescence images showing expression of SOX2,
PAX6, SOX1, and HOXC9, plus low expression of OLIG2 and the absence of TBXT.Scale bars: 100
µm (D) qPCR analysis showing induction of neural progenitor and posterior axial identity markers.
Error bars represent s.d. (n = 3).
Posterior ventral spinal cord progenitor induction medium (see recipe), freshly
prepared
Antibodies for confirming cell identity:
Anti-SOX2 (Abcam, cat. no. ab92494, RRID AB_10585428)
Anti-TBXT (R&D, cat. no. AF2085, RRID AB_2200235)
Anti-PAX6 (Biolegend, cat. no. 901302, RRID AB_2749901)





Figure 3 In vitro differentiation of posterior ventral spinal cord progenitors. (A) Culture conditions
used for induction of posterior ventral spinal cord progenitors. LA, l-ascorbic acid; RA, retinoic acid.
(B) Representative images showing successfully differentiated cells on day 14. (C) Immunofluo-
rescence images showing HOXC9 and OLIG2 expression in day 14 ventral spinal cord progenitors.
Scale bars: 100 µm. (D) qPCR analysis showing expression of ventral spinal cord progenitor and
posterior axial identity markers at day 14. Error bars represent s.d. (n = 3).
Anti-HOXC9 (Abcam, cat. no. ab50839, RRID AB_880494)
Anti-OLIG2 (R&D, cat. no. AF2418, RRID AB_2157554)
Primers for confirming cell identity (see Table 1)
Multiwell cell culture plates

































15-ml conical tubes (Falcon)
Hemocytometer
Additional reagents and solutions for standard antibody staining and qPCR
protocols
Day 3: Prepare Geltrex-coated plates
1. Thaw an aliquot of Geltrex by resuspending 1:100 with cold (4°C) sterile DMEM-
F12 medium.
Thawing quickly with cold medium is important to prevent crystallization.
2. Add Geltrex to cover the entire surface of the multiwell culture plates (150 μl/cm2)
and incubate 1 hr at 37°C/5% CO2.





Days 3-7: Perform posterior neuroectoderm differentiation
3. Aspirate medium from NMPs and add Accutase to cover the cells (150 μl/cm2).
Incubate 5 min at 37°C/5% CO2.
4. Add excess DMEM-F12 (at least 2 vol. relative to Accutase) and triturate gently to
create a single-cell suspension.
5. Transfer cell suspension to a 15-ml Falcon tube and centrifuge 4 min at 200 × g.
6. Resuspend cell pellet in 1 ml of freshly prepared posterior neurectoderm induction
medium supplemented with 10 µM Y-27632.
Small molecules and recombinant proteins should be added to medium fresh each day.
7. Count cells in a 10-µl aliquot using a hemocytometer.
8. Aspirate Geltrex from the culture plates and add 150 μl/cm2 of posterior neurecto-
derm induction medium with 10 µM Y-27632 to each well.
9. Plate cells at a density of 60,000 cells/cm2.
10. Rock gently to distribute the cells evenly across the wells and incubate overnight at
37°C/5% CO2.
11. On days 4 and 6, aspirate medium and replace with fresh medium without Y-27632
(150 μl/cm2).
Y-27632 is included only on days 3 and 7 when cells are replated.
Days 7-14: Perform posterior ventral spinal cord progenitor differentiation
12. On day 7, repeat steps 1-11 to replate cells at a density of 80,000 cells/cm2.
On day 7, before replating, successfully differentiated cells should appear as a confluent
monolayer with clusters/clumps beginning to form (Fig. 2B).
13. On day 8, aspirate medium and replace with fresh medium without Y-27632
(150 μl/cm2).
14. Also on day 8, confirm posterior neuroectoderm cell type by antibody staining and
qPCR.
Successful generation of a posterior neurectoderm identity, at day 8, can be identified by
co-expression of the neural progenitor markers SOX1 and PAX6, together with expres-
sion of CDX2 and posterior HOX PG(6-9), indicating a posterior brachial/thoracic axial
identity (Fig. 2C,D). Furthermore, maintenance of expression of SOX2 (a neural progen-
itor marker) and loss of TBXT (a marker of mesodermal progenitors) indicates efficient
neural conversion of NMPs.
15. On day 9, aspirate medium and replace with fresh medium without Y-27632
(150 μl/cm2).
16. On day 10, aspirate medium and switch to fresh posterior ventral spinal cord pro-
genitor induction medium (150 μl/cm2).
17. On day 12, aspirate medium and replace with fresh medium posterior ventral spinal
cord progenitor induction medium (150 μl/cm2).
Posterior ventral spinal cord progenitor differentiation is complete on day 14. Cells
should display clear signs of forming spiky projections at the edges of colonies (Fig.
3B).
Day 14: Assess differentiation
18. On day 14, confirm the posterior ventral spinal cord progenitor cell type by antibody




Expression of defined ventral/motor neuron progenitor markers NKX6.1, NKX6.2,
OLIG2, and LHX3, by day 14 of differentiation demonstrates efficient induction of ventral
spinal cord progenitors (Fig. 3C,D). Similarly, continued expression of posterior HOX
PG(6-9) genes indicates a robust posterior identity.
BASIC
PROTOCOL 3
DIFFERENTIATION OF POSTERIOR MOTOR NEURONS
The final step of the procedure allows for promotion of a post-mitotic posterior motor
neuron identity. Supplementation with the γ-secretase inhibitor DAPT promotes exit
from a progenitor state, and the presence of neurotrophins promotes neuronal survival
and axonal outgrowth (Fig. 4A).
Materials
Geltrex LDEV-Free Reduced Growth Factor Basement Membrane Matrix (Thermo
Fisher Scientific, cat. no. A1413201), stored in 100-µl aliquots at −80°C
DMEM F-12 medium with 15 mM HEPES, without l-glutamine (Sigma, cat. no.
D6421)
Posterior ventral spinal cord progenitors (see Basic Protocol 2)
Accutase (Sigma, cat. no. A6964)
Motor neuron maturation medium (see recipe), freshly prepared
Antibodies for confirming cell identity:
Anti-ISELT1 (R&D, cat. no. AF1837, RRID AB_2126324)
Anti-ISLET1/2 (DSHB, cat. no. 39.4D5, RRID AB_2314683)
Anti-neurofilament (Abcam, cat. no. ab8135, RRID AB_306298)
Anti-nNOS (Thermo Fisher Scientific, cat. no. 37-2800, RRID AB_2533308)
Anti-MNX1 (DSHB, cat. no. 81.5C10, RRID AB_2145209)
Anti-cholinergic acetyltransferase (Abcam, cat. no. ab144P, RRID AB_90661)
Primers for confirming cell identity (see Table 1)
Multiwell cell culture plates
37°C/5% CO2 incubator
15-ml conical tubes (Falcon)
Hemocytometer
Additional reagents and equipment for standard antibody staining, qPCR, and
patch-clamp recording protocols
Day 14: Perform posterior motor neuron differentiation
1. On day 14, prepare fresh Geltrex-coated plates as described (see Basic Protocol 2,
steps 1-2).
2. Aspirate medium from ventral cord progenitor cells and add Accutase (150 μl/cm2)
to cover the cells. Incubate 5 min at 37°C/5% CO2.
3. Add excess DMEM-F12 (at least 2 vol. relative to Accutase) and triturate gently to
create a single-cell suspension.
4. Transfer cell suspension to a 15-ml Falcon tube and centrifuge 4 min at 200 × g.
5. Resuspend cell pellet in 1 ml of freshly prepared motor neuron maturation medium
supplemented with 10 µM Y-27632.
Small molecules and recombinant proteins should be added to medium fresh each day.
6. Count cells in a 10-µl aliquot using a hemocytometer.
7. Aspirate Geltrex from the culture plates and add 150 μl/cm2 of motor neuron matu-




Figure 4 In vitro differentiation of posterior MNs. (A) Culture conditions used for induction of pos-
terior MNs. LA, l-ascorbic acid; RA, retinoic acid. (B) Representative images showing cells on day
24 after successful posterior MN differentiation. (C) Immunofluorescence images showing expres-
sion of the MN-specific markers ISLET1, neurofilament, MNX1, and ChAT as well as the pregan-
glionic motor column marker nNOS. Scale bars: 100 µm (D) qPCR analysis showing induction of




8. Plate cells at a density of 100,000 cells/cm2.
9. Rock gently to distribute the cells evenly across the wells and incubate 48 hr at
37°C/5% CO2.
10. On days 16, 18, 20, and 22, aspirate medium and replace with fresh motor neuron
maturation medium without Y-27632 (150 μl/cm2).
Y-27632 is included only on day 14 when cells are replated.
Axonal projections should be clearly visible on day 16.
Day 24: Assess differentiation
11. On day 24, confirm posterior motor neuron differentiation by antibody staining,
qPCR, and electrophysiology.
On day 24, posterior motor neuron differentiation should be complete. Cells should dis-
play clear clusters of neuronal cell bodies with fasciculated axonal projections to adja-
cent clusters (Fig. 4A). A mature motor neuron identity can be confirmed by expression
of ISLET1, MNX1, cholinergic acetyltransferase (ChAT), and neurofilament (Fig. 4C,D).
Expression of HOX PG(6-9) indicates a posterior motor neuron identity, while expression
of nNOS suggests a high yield of thoracic-specific preganglionic motor column character
(Fig. 4C,D). Electrophysiological functionality, displayed through whole-current patch-
clamp recordings, can also be used to demonstrate the functional maturity of the derived
motor neurons (Wind et al., 2021).
REAGENTS AND SOLUTIONS
Motor neuron maturation medium
49.7 ml 1× N2B27 medium (see recipe)
20 ng/ml recombinant BDNF
20 ng/ml recombinant GDNF
200 μM l-ascorbic acid
10 μM γ-secretase inhibitor DAPT
10 μM Y-27632 (on day 14 only)
Prepare fresh each day
Y-27632 is used only for replating ventral spinal cord progenitors.
N2B27 medium
94 ml 1× DMEM F-12 with 15 mM HEPES and no l-glutamine (Sigma, cat. no.
D6421)
94 ml 1× Neurobasal Medium (Thermo Fisher Scientific, cat. no. 21103-049)
2 ml 100× N-2 Supplement (Thermo Fisher Scientific, cat. no. 17502-001; final
1×)
4 ml 50× B-27 Serum-Free Supplement (Thermo Fisher Scientific, cat. no.
17504-001; final 1×)
2 ml 100× MEM Non-Essential Amino Acids (Thermo Fisher Scientific, cat. no.
11140-035; final 1×)
2 ml 100× Glutamax (Thermo Fisher Scientific, cat. no. 35050-038; final 1×)
200 μl 50 mM 2-mercaptoethanol (Thermo Fisher Scientific, cat. no. 31350-010;
final 100 μM)
2 ml 100× penicillin-streptomycin (final 1×; optional)
Store up to 3 weeks at 4°C
On the day of use add:
20 ng/ml recombinant basic FGF
3 μM CHIR99021




10 µM Y-27632 (on days 1, 3, 7 only)
CHIR99021 is a GSK-3 inhibitor, LDN193189 is an ALK2/ALK3 inhibitor, and Y-27632 is a
Rho-kinase inhibitor. Y-27632 is used only for seeding hPSCs and replating NMPs.
Posterior neurectoderm induction medium








100 nM all-trans retinoic acid
Prepare fresh each day
Posterior ventral spinal cord progenitor induction medium
49.7 ml 1× N2B27 medium (see recipe)
500 nM SAG
1 μM purmorphamine
100 nM all-trans retinoic acid
20 ng/ml recombinant BDNF
20 ng/ml recombinant GDNF
200 μM l-ascorbic acid
Prepare fresh each day
Small molecule and protein stock solutions
All-trans retinoic acid (Tocris, cat. no. 0695), 1 mM in DMSO, stored in 200-µl
aliquots at −20°C
L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrate (Sigma, cat. no.
A8960), 200 mM in sterile H2O, stored in 200-µl aliquots at −20°C
CHIR99021 (Tocris, cat. no. 4423): 10 mM in DMSO, stored in 200-µl aliquots at
−20°C
DAPT (Sigma, cat. no. D5942), 10 mM in DMSO, stored in 100-µl aliquots at
−20°C
DMH1 (Tocris cat. no. 4126), 10 mM in DMSO, stored in 50-µl aliquots at −20°C
LDN193189 dihydrochloride (Tocris, cat. no. 6053): 1 mM in DMSO, stored in
50-µl aliquots at −20°C
Purmorphamine (Sigma cat. no. SML0868), 10 mM in DMSO, stored in 50-µl
aliquots at −20°C
Recombinant human/murine/rat BDNF (Peprotech, cat. no. 450-02), 10 µg/ml in
PBS, stored in 200-µl aliquots at −20°C
Recombinant human FGF-basic (154 a.a.; Peprotech, cat. no. 100-18B): 10 µg/ml
in PBS, stored in 200-µl aliquots at −20°C
Recombinant human GDNF (Peprotech, cat. no. 450-10), 10 µg/ml in PBS, stored
in 200-µl aliquots at −20°C
SAG (Tocris cat. no. 4366), 10 mM in DMSO, stored in 50-µl aliquots at −20°C
SB431542 (Tocris cat. no. 1614), 10 mM in DMSO, stored in 50-µl aliquots at
−20°C
Y-27632 dihydrochloride (Adooq Biosciences, cat. no. A11001): 10 mM in
DMSO, stored 200-µl aliquots at −20°C







Because damage or degeneration of MNs
occurs in a wide array of movement-based dis-
orders, the in vitro generation of MNs of de-
fined A-P identities from hPSCs has been the
focus of intense research.
Conventional MN differentiation proto-
cols typically rely on induction of an early
anterior neural identity through exposure
to TGF-β and BMP inhibitors (Amoroso
et al., 2013; Chambers et al., 2009). Sub-
sequent treatment with SHH agonists has
been globally utilized to promote a ventral
character, whereas simultaneous exposure to
retinoic acid is designed to promote more
caudal identities. However, MNs produced
through this approach exhibit a predomi-
nantly hindbrain/cervical/upper brachial char-
acter marked by expression of HOX PG(1-6)
members and innervating the anterior muscu-
lature upon in vivo transplantation (Amoroso
et al., 2013; Soundararajan, Miles, Rubin,
Brownstone, & Rafuse, 2006).
During amniote embryonic development,
posteriorly located neuromesodermal progen-
itors have been shown to give rise to cell
lineages of the post-cranial axis (Cambray
& Wilson, 2007; Tzouanacou et al., 2009;
Wymeersch et al., 2016). Similarly, NMP-like
cells generated in vitro from hPSCs can also be
steered towards posterior neural, mesodermal,
and neural crest lineages (Cooper et al., 2021;
Frith et al., 2018; Gouti et al., 2014; Lippmann
et al., 2015; Mouilleau et al., 2021; Turner,
Rué, Mackenzie, Davies, & Martinez Arias,
2014; Verrier, Davidson, Gierliński, Dady, &
Storey, 2018). Moreover, we have recently
shown that the efficient generation of poste-
rior thoracic HOX PG(6-9) motor neurons is
best achieved by differentiating through a neu-
romesodermal progenitor intermediary state
(Wind et al., 2021). This strategy relies on ex-
posure of hPSC-derived NMPs to TGF-β and
BMP inhibitors to promote a posterior neu-
ral tube identity, similar to that observed by
Verrier et al. (2018). Further differentiation in
the presence of Shh signals and TGF-β and
BMP inhibitors coordinate more efficient ven-
tralization to promote a MN identity, while
continued high levels of FGF and Wnt sig-
nals are required to promote a posterior axial
identity (Mouilleau et al., 2021; Wind et al.,
2021).
Our differentiation strategy gives rise
to cultures predominantly marked by high
levels of HOX PG(8-9) transcripts and
large numbers of HOXC9-ISLET1-nNOS
co-expressing/MNX1-negative MNs, thus
demonstrating a thoracic preganglionic
columnar character. However, we have also
detected the presence of more anterior (PG4-
6) and posterior (PG10) HOX transcripts,
indicative of potential co-emergence of MN
subpopulations of a brachial and lumbar axial
identity, respectively (Wind et al., 2021).
Moreover, MNX1 positivity may reflect
the induction of MNs of lateral, medial, or
hypaxial motor column character.
Critical Parameters
Quality of hPSC cultures
Prior to use in differentiation protocols,
it is essential to ensure that the hPSCs have
retained pluripotency, which can be observed
by screening for pluripotency markers using
immunofluorescence and flow cytometry.
A reduction in pluripotency and observed
spontaneous differentiation in hPSC cultures
can result in inefficient differentiation, and
cultures with high levels of spontaneous dif-
ferentiation or reduced pluripotency marker
expression should be disposed. Screening for
genetic abnormalities is also important, as
specific aberrations can impair hPSC differ-
entiation capabilities. Good practices such as
regular culture medium changes, passaging
cells once they reach 70%-80% confluency,
and discarding cells that have a high passage
number can ensure better hPSC quality. The
protocol described here has been optimized
using hPSCs cultured on vitronectin- and
laminin-521-coated surfaces in Essential 8
medium. It is important to note that cul-
turing hPSCs on different substrates and in
different media can impact downstream dif-
ferentiation efficiencies, and therefore further
optimization may be required.
Titration of small molecule concentrations
We have found that levels of WNT, TGF-
β, and BMP signals must be tightly regulated
to allow both efficient neural induction and
subsequent ventralization. Titration of TGF-
β and BMP inhibitor and CHIRON concen-
trations is essential when using different cell
lines, likely due to differences in endogenous
signaling levels.
Cell density
It is important to ensure that the optimum
number of cells is seeded at the indicated time





Table 2 Troubleshooting Guidelines
Problem Possible solution
Low hPSC quality Do not grown hPSCs past 80% confluency
Change medium daily
Send cells for routine genetic screening and discard if any genetic aberrations are
found
Discard hPSCs once they reach a high passage number (e.g., >20 passages) or if
spontaneous differentiation is observed
Contamination in cell
culture
Maintain a sterile working environment at all times when working with cells
Clean incubators, tissue culture hoods, and water baths regularly
During long-term differentiation, include pen-strep or an equivalent antibiotic in the




When lifting cells for replating, ensure that Accutase is not left on cells for an
extended period of time (e.g., >5 min)
Do not be handle cells harshly or abrasively when lifting or resuspending them
Be sure to seed cells in medium containing 10 µM Y-27632 for at least 24 hr
Ensure that plates are coated with vitronectin or Geltrex long enough for full surface





Titrate concentrations of TGF-β and BMP inhibitors to identify optimal
concentrations for neural induction (levels of endogenous TGF-β and BMP can vary
between cell lines)
Aliquot small molecules in small volumes to prevent repeated freezing and thawing
Low induction yield of
ISLET1+ posterior motor
neurons
Optimize cell density when replating on day 14 of differentiation
Ensure that cells replated on day 14 are enriched in expression of ventral spinal cord
progenitor markers
Increase exposure to Y-27632 from 24 hr to 48 hr to enhance formation of axonal
projections
Difficulty lifting/detaching
neurons at later stages of
differentiation
At later stages of differentiations (day 18 onwards), the neurons will form foci with
bundled axons, which can be fragile and prone to movement. To address this:
Always apply medium gently to the wall of the plate wells; avoid applying it
harshly or directly onto the cells
Conduct half medium changes by gently aspirating only half of the medium at a
time, as this can be gentler for the cells
Supplement media with additional Geltrex during medium replacement to enhance
neuron adhesion
The cells are highly proliferative between days
3 and 10 of differentiation, so it is important to
plate cells at the correct densities on days 3 and
7 to prevent over-confluency and cell death.
We have recommended optimal densities at
each stage, but these should be fully opti-
mized by each user and for individual hPSC
lines.
Troubleshooting
For troubleshooting guidelines, see Table 2.
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